Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 44,273 | 65,813 | 14,311 | 46,329 | 71,144 |
| Marketable Securities | 14,239 | 28,300 | 130,983 | 206,669 | 330,171 |
| Receivables | N/A | N/A | 2,405 | 11,738 | 8,032 |
| TOTAL | $61,123 | $97,830 | $153,113 | $315,243 | $448,445 |
| Non-Current Assets | |||||
| PPE Net | 2,528 | 3,660 | 4,961 | 7,728 | 17,453 |
| Investments And Advances | 2,104 | 1,614 | 2,780 | 2,007 | 3,907 |
| Intangibles | 0 | 0 | 0 | 12,643 | 13,140 |
| Other Non-Current Assets | 8,555 | 10,094 | 10,097 | 10,912 | 12,997 |
| TOTAL | $13,187 | $15,367 | $17,838 | $33,291 | $47,497 |
| Total Assets | $74,310 | $113,197 | $170,951 | $348,533 | $495,942 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,128 | 17,551 | 20,918 | 80,907 | 48,193 |
| Accrued Expenses | 651 | 2,022 | 2,365 | 10,594 | 10,326 |
| Other current liabilities | 29,067 | 13,255 | N/A | N/A | N/A |
| TOTAL | $43,669 | $35,326 | $42,570 | $96,868 | $65,742 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 109 | 2,563 | 4,619 |
| Other Non-Current Liabilities | 6,545 | 9,368 | 11,032 | 29,271 | 30,434 |
| TOTAL | $6,545 | $9,368 | $11,032 | $29,303 | $30,530 |
| Total Liabilities | $50,214 | $44,693 | $53,602 | $126,171 | $96,272 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 69,092 | 36,667 | 23,370 | 21,669 | 18,110 |
| Common Shares | 69 | 36 | 23 | 21 | 217 |
| Retained earnings | -1,815,165 | -1,730,219 | -1,622,965 | -1,487,848 | -1,209,855 |
| Other shareholders' equity | -638 | -676 | -663 | -698 | -283 |
| TOTAL | $24,096 | $68,504 | $117,349 | $222,363 | $399,669 |
| Total Liabilities And Equity | $74,310 | $113,197 | $170,951 | $348,533 | $495,942 |